Literature DB >> 3912013

Could aminoglutethimide replace adrenalectomy?

A L Harris.   

Abstract

Could aminoglutethimide replace adrenalectomy? This question has already been answered in clinical practice in the United Kingdom, for surgical adrenalectomy has declined markedly in frequency as new hormonal therapy has appeared. An optimal assessment of an endocrine therapy can only be made in previously untreated patients because of the heterogeneity of previously treated populations. Thus aminoglutethimide (AG) and adrenalectomy have been compared for previously untreated and treated populations. Because AG is commonly called 'medical adrenalectomy', this article will review and compare aminoglutethimide therapy with surgical adrenalectomy and make the case that surgical adrenalectomy is no longer indicated in the management of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3912013     DOI: 10.1007/bf01806770

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  73 in total

1.  Stereoselective inhibition of cholesterol side chain cleavage by enantiomers of aminoglutethimide.

Authors:  V I Uzgiris; C A Whipple; H A Salhanick
Journal:  Endocrinology       Date:  1977-07       Impact factor: 4.736

2.  Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.

Authors:  R J Santen; S Santner; B Davis; J Veldhuis; E Samojlik; E Ruby
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

3.  Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

Authors:  R Cash; A J Brough; M N Cohen; P S Satoh
Journal:  J Clin Endocrinol Metab       Date:  1967-09       Impact factor: 5.958

Review 4.  Aminoglutethimide: a "side-effect" turned to therapeutic advantage.

Authors:  S W Hughss; D M Burley
Journal:  Postgrad Med J       Date:  1970-07       Impact factor: 2.401

5.  Metabolism of aminoglutethimide in humans: identification of hydroxylaminoglutethimide as an induced metabolite.

Authors:  M Jarman; A B Foster; P E Goss; L J Griggs; I Howe; R C Coombes
Journal:  Biomed Mass Spectrom       Date:  1983-11

6.  Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.

Authors:  S B Kaye; R L Woods; R M Fox; A S Coates; M H Tattersall
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

7.  Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy.

Authors:  B V Lawrence; A Lipton; H A Harvey; R J Santen; S A Wells; C E Cox; D S White; E K Smart
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

8.  Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen.

Authors:  A U Buzdar; K C Powell; S S Legha; G R Blumenschein
Journal:  Cancer       Date:  1982-11-01       Impact factor: 6.860

9.  Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors.

Authors:  Y J Abul-Hajj
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

10.  Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.

Authors:  A L Harris; M Dowsett; I E Smith; S L Jeffcoate
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

View more
  2 in total

Review 1.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

2.  Long term survival and the prognostic factors of advanced breast cancer patients treated with adreno-oophorectomy.

Authors:  Y Nomura; H Tashiro; A Osaki
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.